Muscular dystrophies: Histology, immunohistochemistry, molecular genetics and management

Current Pharmaceutical Design

Volumn 16, Issue 8, 2010, Pages 978-987

  Lamperti, Costanza ^a   Moggio, Maurizio ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

CMD; Dystrophies; Exon skipping; LGMD; Theraphy

Indexed keywords

MYOSTATIN; PARVOVIRUS VECTOR; TRANSFORMING GROWTH FACTOR BETA1;

CELL THERAPY; CONNECTIVE TISSUE; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; HISTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIMB GIRDLE MUSCULAR DYSTROPHY; MOLECULAR GENETICS; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE NECROSIS; MUSCLE REGENERATION; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; PRIORITY JOURNAL; REVIEW;

GENE THERAPY; HUMANS; MODELS, BIOLOGICAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MUTATION; MYOSTATIN; STEM CELL TRANSPLANTATION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77950240417     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790883471     Document Type: Review

References (101)

1. Muntoni F, Voit TC. The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul Disord 2004; 14: 635-649
2. Fagiolari G, Cappellini A, Cagliani R, Prelle A, Lucchini V, Fortunato F, et al. Muscular dystrophy: central nervous system α-dystroglycan glycosylation defects and brain malformation. J Child Neurol 2009; in press.
3. Bertini E, Pepe G. Collagen type VI and related disorders: bethlem myopathy and Ullrich scleroatonic muscular dystrophy. Eur J Paediatr Neurol 2002; 6(4): 193-198
4. Quijano-Roy S, Renault F, Romero N, Guicheney P, Fardeau M, Estournet B. EMG and nerve conduction studies in children with congenital muscular dystrophy. Muscle Nerve 2004; 29: 292-299
5. Jones K, North K. The congenital muscular dystrophies. In: Jones HR, De Vivo DC, Darras BT, Eds. Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach. Philadelphia: Butterworth Heinemann 2003; pp. 633-644.
6. Dubowitz V, Fardeau M. Proceedings of the 27th ENMC sponsored workshop on congenital muscular dystrophy. Neuromuscul Disord 1995; 5: 253-258
7. van Reeuwijk J, Janssen M, van den Elzen C, Beltran-Valero de Bernabé D, Sabatelli P, Merlini L, et al. POMT2 mutations cause α-dystroglycan hypoglycosylation and Walker Warburg syndrome. J Med Genet 2005; 42(12): 907-912
8. Longman C, Brockington M, Torelli S, Jimenez-Mallebrera C, Kennedy C, Khalil N, et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha dystroglycan. Hum Mol Genet 2003; 12(21): 2853-2861
9. Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci 2006; 119(Pt 2): 199-207.
10. Cohn RD. Dystroglycan: important player in skeletal muscle and beyond. Neuromuscul Disord 2005; 15(3): 207-217
11. Muntoni F, Brockington M, Blake JD, Torelli S, Brown SC. Defective glycosylation in muscular dystrophy. Lancet 2002; 360(9343): 1419-1421
12. Muntoni F, Brockington M, Godfrey C, Ackroyd M, Robb S, Manzur A, et al. Muscular dystrophies due to defective glycosylation of dystroglycan. Acta Myol 2007; 26(3): 129-135
13. Mercuri E, Messina S, Bruno C, Mora M, Pegoraro E, Comi GP, et al. Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study. Neurology 2009; 72(21): 1802-1809
14. Rankin J, Ellard S. The laminopathies: a clinical review. Clin Genet 2006; 70(4): 261-74. Review. Erratum in: Clin Genet 2007; 71(3): 293.
15. Darras BT. Molecular genetics of Duchenne and Becker muscular dystrophy. J Pediatr 1990; 117: 1-15.
16. Manzur AY, Muntoni F. Diagnosis and new treatments in muscular dystrophies. J Neurol Neurosurg Psychiatry 2009; 80(7): 706-714
17. Darras BT. Muscular dystrophies. Continuum 2006; 12: 33-75.
18. Wicksell RK, Kihlgren M, Melin L, Eeg-Olofsson O. Specific cognitive deficits are common in children with Duchenne muscular dystrophy. Dev Med Child Neurol 2004; 46: 154-159
19. Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy: I. Natural history. J Neurol 1993; 240: 98-104.
20. Gedeon AK, Wilson MJ, Colley AC, Sillence DO, Mulley JC. X linked fatal infantile cardiomyopathy maps to Xq28 and is possibly allelic to Barth syndrome. J Med Genet 1995; 32: 383-388
21. Gospe SM, Lazaro RP, Lava NS, Grootscholten PM, Scott MO, Fischbeck KH. Familial X-linkedmyalgia and cramps: a nonprogressive myopathy associated with a deletion in the dystrophin gene. Neurology 1989; 39: 1277-1280
22. Sunohara N, Arahata K, Hoffman EP, Yamada H, Nishimiya J, Arikawa E, et al. Quadricepsmyopathy: forme fruste of Becker muscular dystrophy. Ann Neurol 1990; 28: 634-639
23. Hoffman EP, Kunkel LM. Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron 1989; 1019-1029
24. Hoogerwaard EM, van der Wouw PA, Wilde AA, Bakker E, Ippel PF, Oosterwijk JC, et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 1999; 9: 347-351
25. Hoffman EP, Arahata K, Minetti C, Bonilla E, Rowland LP. Dystrophinopathy in isolated cases of myopathy in females. Neurology 1992; 42: 967-975
26. Pikó H, Vancsó V, Nagy B, Bán Z, Herczegfalvi A, Karcagi V. Dystrophin gene analysis in Hungarian Duchenne/Becker muscular dystrophy families - detection of carrier status in status in symptomatic and asymptomatic female relatives. Neuromuscul Disord 2009; 19(2): 108-112
27. Bushby KMD. The limb-girdle muscular dystrophies - multiple genes, multiple mechanisms. Hum Mol Genet 1999; 8: 1875-1882
28. D'Amico A, Tessa A, Bruno C, Petrini S, Biancheri R, Pane M, et al. Expanding the clinical spectrum of POMT1 phenotype. Neurology 2006; 66: 1564-1567
29. Guglieri M, Magri F, Comi GP. Molecular etiopathogenesis of limb girdle muscular and congenital muscular dystrophies: boundaries and contiguities. Clin Chim Acta 2005; 361: 54-79.
30. Guglieri M, Magri F, D'Angelo MG. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat 2008; 29(2): 258-266
31. Guglieri G, Straub V, Bushby K, Lochmüller H. Limb-girdle muscular dystrophies. Curr Opin Neurol 2008; 21: 576-584
32. Clement EM, Godfrey C, Tan J, Brockington M, Torelli S, Feng L, et al. Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant. Arch Neurol 2008; 65: 137-141
33. Biancheri R, Falace A, Tessa A, Pedemonte M, Scapolan S, Cassandrini D, et al. POMT2 gene mutation in limb-girdle muscular dystrophy with inflammatory changes. Biochem Biophys Res Commun 2007; 363: 1033-1037
34. Godfrey C, Clement E, Mein R, Brockington M, Smith J, Talim B, et al. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 2007; 130: 2725-2735
35. Griggs RC, Moxley RT, 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991; 48: 383-388
36. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. Randomized, doubleblind six-month trial of prednisone in Duchenne's muscular dystrophy. New Engl J Med 1989; 320: 1592-1597
37. Moxley RT, III, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005; 64: 13-20
38. Manzur AY, Kukntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy (Review). Cochrane Libr 2006: 1-41.
39. Alman BA, Raza SN, Biggar WD. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy. J Bone Joint Surg Am 2004; 86-A: 519-524
40. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscl Disord 2006; 16: 249-255
41. King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, Hoyle C, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007; 68: 1607-1613
42. Eagle M, Baudouin S, Chandler C, Giddings DR, Bullock R, Bushby K, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967and the impact of home nocturnal ventilation. Neuromuscl Disord 2002; 12: 926-929
43. Mohr CH, Hill NS. Long-term follow-up of nocturnal ventilatory assistance in patients with respiratory failure due to Duchennetype muscular dystrophy. Chest 1990; 97: 91-96
44. Simonds AK, Muntoni F, Heather S, Fielding S. Impact of nasal ventilation on survival in ypercapnic Duchenne muscular dystrophy. Thorax 1998; 53: 949-952
45. Wagner KR. Approaching a new age in duchenne muscular dystrophy treatment. Neurotherapeutics 2008; 5(4): 583-591
46. Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscl Disord 2008; 18: 365-370
47. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Bécane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005; 45: 855-857
48. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med 1987; 316: 1429-1435
49. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med 1991; 325: 293-302.
50. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomaticheart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587
51. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002; 82: 291-329.
52. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 1961; 9: 493-495
53. Holterman CE, Rudnicki MA. Molecular regulation of satellite cell function. Semin Cell Dev Biol 2005; 16: 575-584
54. Muntoni F, Wells D. Genetic treatments in muscular dystrophies. Curr Opin Neurol 2007; 20: 590-594
55. Cossu G, Sampaolesi M. New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. Trends Mol Med 2007; 13(12): 520-526
56. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. New Engl J Med 2007; 357: 2677-2686
57. Muntoni F. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009; 8(10): 918-928
58. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999; 104: 375-381
59. Dunant P, Walter MC, Karpati G, Lochmuller H. Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 2003; 27: 624-627
60. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, et al. Safety, tolerability and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administrationto healthy male and female adult volunteers. J Clin Pharmacol 2007; 47: 430-444
61. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000; 95: 10158-10163
62. Fabb SA, Wells DJ, Serpente P, Dickson G. Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micodystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/ mdx mice. Hum Mol Genet 2002; 11: 733-741
63. Liu M, Yue Y, Harper SQ, Grange RW, Chamberlain JS, Duan D. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther 2005; 11: 245-256
64. Farini A, Razini P, Erratico S, Torrente Y, Meregalli M. Cell based therapy for duchenne muscular dystrophy. J Cell Physiol 2009; 221(3): 526-534
65. Montarras D, Morgan J, Collins C, Relaix F, Zaffran S, Cumano A, et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science 2005; 23; 309(5743): 2064-2067
66. Péault B, Rudnicki M, Torrente Y, Cossu G, Tremblay JP, Partridge T, et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 2007; 15: 867-877
67. Minasi MG, Riminucci M, De Angelis L, Borello U, Berarducci B, Innocenzi A, et al. The meso-angioblast: a multipotent, selfrenewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 2002; 129: 2773-2783
68. Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, D'Antona G, Pellegrino MA, et al. Cell therapy of alpha sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 2003; 301: 487-492
69. Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, Innocenzi A, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006; 444: 574-579
70. Berry SE, Liu J, Chaney EJ, Kaufman SJ. Multipotential mesoangioblast stem cell therapy in the mdx/utrn-/- mouse model for Duchenne muscular dystrophy. Regen Med 2007; 2: 275-288
71. Davies KE, Ground MD. Treating muscular dystrophy with stem cells? Cell 2007; 127: 1304-1306
72. Bretag A. Too much hype, not enough hope: Are balanced reporting and proper controls too much to expect from therapeutic studies in animal models of neuromuscular diseases that presage clinical trials in humans? Neuromuscul Disord 2007; 17: 203-205
73. Schessl J. Clinical trial immunosuppressive treatment in Duchenne muscular dystrophy - update. Neuropediatrics 2005; DOI:10.1055/s-2005-867995 (http: //www.thieme-connect.com/ejournals)
74. Stupka N, Gregorevic P, Plant DR, Lynch GS. The calcineurin signal transduction pathway is essential for successful muscle regeneration in the mdx dystrophic mice. Acta Neuropathol 2004; 107: 299-310.
75. St-Pierre SJG, Chakkalakal JV, Kolodziejczyk SM, Knudson JC, Jasmin BJ, Megeney LA. Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NFAT pathway. FASEB J 2004; 18: 1937-1939
76. Parsons SA, Millay DP, Sargent MA, Naya FJ, McNally EM, Sweeney HL, et al. Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy. J Biol Chem 2007; 282: 10068-10078
77. Gussoni E, Soneoka Y, Strickland CD, Buzney EA, Khan MK, Flint AF, et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999; 401: 390-394
78. Dezawa M. al Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 2005; 309: 314-317
79. Bachrach E, Li S, Perez AL, Schienda J, Liadaki K, Volinski J, et al. Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. Proc Natl Acad Sci USA 2004; 101: 3581-3586
80. Dell'Agnola C, Wang Z, Storb R, Tapscott SJ, Kuhr CS, Hauschka SD, et al. Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs. Blood 2004; 104: 4311-4318
81. Lapidos KA, Chen YE, Earley JU, Heydemann A, Huber JM, Chien M, et al. Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftment into cardiac and skeletal muscle. J Clin Invest 2004; 114, 1577-1585
82. Torrente Y, Belicchi M, Marchesi C, Dantona G, Cogiamanian F, Pisati F, et al. Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplant 2007; 16: 563-577
83. Benchaouir R, Meregalli M, Farini A, D'Antona G, Belicchi M, Goyenvalle A, et al. Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell 2007; 1(6): 646-657
84. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 1997; 387: 83-90.
85. Lee S-J. Sprinting without myostatin: a genetic determinant of athletic prowess. Trends Genet 2007; 23: 475-477
86. Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Kömen W, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. New Engl J Med 2004; 350: 2682-2688
87. Lee SJ. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 2004; 20: 61-86.
88. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420: 418-421
89. Qiao C, Li J, Jiang J, Zhu X, Wang B, Li J, et al. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther 2008; 19: 241-254
90. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008; 63: 561-571
91. Benabdallah BF, Bouchentouf M, Rousseau J, Bigey P, Michaud A, Chapdelaine P, et al Inhibiting myostatin with follistatin improves the success of myoblast transplantation in dystrophic mice. Cell Transplant 2008; 17(3): 337-350
92. Allen RE, Boxhorn LK. Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-β. J Cell Physiol 1987; 1987: 576-582
93. Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, et al. Transforming growth factorbeta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol 2004; 164: 1007-1019
94. Olson EN, Sternberg E, Hu JS, Spizz G, Wilcox C, et al. Regulation of myogenic differentiation by type β transforming growth factor. J Cell Biol 1986; 103: 1799-1805
95. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, et al. Expression of transforming growth factor-beta1 in dystrophic patient muscles correlates with fibrosis. J Clin Invest 1995; 96: 1137-1144
96. Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, et al. Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy. Neurology 2005; 65: 826-834
97. Zanotti S, Negri T, Cappelletti C, Bernasconi P, Canioni E, Di Blasi C, et al. Decorin and biglycan expression is differentially altered in several muscular dystrophies. Brain 2005; 128: 2546-2555
98. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, et al. Angiotensin II type 1receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007; 13: 204-210
99. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Fibrate-associated adverse effects beyond muscle and liver toxicity. Curr Pharm Des 2008; 14(6): 574-587
100. Fu DX, Foss CA, Nimmagadda S, Ambinder RF, Pomper MG. Imaging virus-associated cancer. Curr Pharm Des 2008; 14(28): 3048-3065
101. Rovere-Querini P, Brunelli S, Clementi E, Manfredi AA. Cell death: tipping the balance of autoimmunity and tissue repair. Curr Pharm Des 2008; 14(3): 269-277